Macquarie Group LTD Black Diamond Therapeutics, Inc. Transaction History

Macquarie Group LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$2.67 - $5.74 $3,155 - $6,784	1,182 New	1,182 $5,000
Q4 2021 Feb 11, 2022	SELL	$5.18 - $8.48 $896 - $1,467	-173 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$12.19 - $28.17 $368,235 - $850,959	-30,208 Reduced 99.43%	173 $2,000
Q1 2021 May 14, 2021	BUY	$22.23 - $34.75 $96,078 - $150,189	4,322 Added 16.59%	30,381 $737,000
Q4 2020 Feb 16, 2021	BUY	$29.47 - $35.0 $71,700 - $85,155	2,433 Added 10.3%	26,059 $835,000
Q3 2020 Nov 13, 2020	BUY	$26.17 - $43.07 $611,619 - $1.01 Million	23,371 Added 9165.1%	23,626 $715,000
Q2 2020 Aug 11, 2020	BUY	$22.3 - $44.8 $5,686 - $11,424	255 New	255 $11,000

117

48.8M

1.84M

1.93M

Ticker BDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,339,500
Market Cap $79.2M
Description
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.